None listed
Conditions
Interventions
Drug : 1)Group A (Treatment arm)
Patients in the eradication arm receive the standard regimen consisting of proton pump inhibitor (esomeprazole 40 mg), amoxicillin 1 g, and clarithromycin 500 mg twice
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) aged 19–70 years (2) who are diagnosed with H. pylori infection (3) who are diagnosed with pathologic stage 1 gastric cancer (4) who received distal gastrectomy for cancer located in the lower half of the stomach (pylorus, antrum, and lower body), and who received proximal gastrectomy for cancer located in the upper half of the stomach (fundus, cardia, upper body, and mid body) either requiring upfront curative gastrectomy or additional surgery after non-curative endoscopic resection (5) not indicated to adjuvant chemotherapy
Exclusion criteria
Exclusion criteria: (1) history of HPE (2) history of previous gastrectomy (3) history of any malignancy within recent 10 years (4) Patient who previously undergone endoscopic treatment on the section that will become the remnant stomach (5) patients who require neoadjuvant chemotherapy (6) history of allergy or serious adverse events to prescribed medication including amoxicillin and clarithromycin (7) presence of severe comorbidity (e.g. cardiac, hepatic, or renal insufficiency) or coagulopathy (8) pregnant or lactating women (9) presence of psychiatric disorder that may preclude compliance (10) patients who cannot understand informed consent. (11) Borrmann type 4 tumors (linitis plastica) on tumor classification (12) Proximal resection margin shorter than 3cm in cases of advanced gastric cancer (13) Declined to participate (14) Withdrew consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The development of gastric neoplasms, including adenoma or adenocarcinoma in the remnant stomach of patients who received curative gastrectomy for gastric cancers | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) the 10-year overall survival, 2) the improvement rates of the gastric glandular atrophy and/or intestinal metaplasia, 3) HP eradication success rate, and 4) the incidence of new-onset hyperplastic polyps | — |
Countries
Korea, Republic of
Contacts
Public ContactChang Seok Ko
Asan Medical Center
Outcome results
None listed